...
首页> 外文期刊>International Journal of Pharmaceutics >Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly (lactide-co-glycolide) nanoformulation
【24h】

Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly (lactide-co-glycolide) nanoformulation

机译:通过使用新型阳离子聚(丙交酯-乙交酯)纳米配方共同递送靶向siRNA和阿霉素的MDR1来逆转体外的多药耐药性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Over expression of drug efflux transporters such as P-glycoprotein (P-gp) cumulatively leading to multidrug resistance (MDR) embodies a major hindrance for successful cancer therapy. A paradigm nanomedicinal approach involving an anticancer drug and modulators of drug resistance within one multifunctional nanocarrier-based delivery system represent an ideal modality for the treatment of MDR. In this regards, we have developed a cationic polymeric nanoparticulate system loaded with MDR1-siRNA and doxorubicin. Results indicated augmented synergistic effect of combinational nanoformulation in overcoming MDR in MCF-7/ADR cells. Therefore, the above regime could be a promising co-delivery system for effective therapy of drug resistant breast cancer.
机译:药物外排转运蛋白如P-糖蛋白(P-gp)的过度表达累积导致多药耐药性(MDR)成为成功癌症治疗的主要障碍。在一个基于多功能纳米载体的递送系统中涉及抗癌药物和耐药性调节剂的范式纳米医学方法代表了治疗MDR的理想方式。在这方面,我们已经开发了一种载有MDR1-siRNA和阿霉素的阳离子聚合物纳米颗粒系统。结果表明,组合纳米制剂在克服MCF-7 / ADR细胞中的MDR方面具有增强的协同作用。因此,上述方案对于有效治疗耐药性乳腺癌可能是有希望的共同递送系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号